Lincoln Pharmaceuticals Limited shareholders approved the declaration of a final dividend of ₹1.80 per equity share for FY26 during its 32nd Annual General Meeting (AGM) held on September 30, 2026.

The meeting was conducted through Video Conferencing and Other Audio-Visual Means in compliance with Ministry of Corporate Affairs and SEBI circulars. Voting results were submitted to stock exchanges on October 3, 2026, pursuant to Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dividend and Financial Statements Approval

Shareholders voted overwhelmingly in favor of adopting the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. The resolution received 99.99% votes in favor across all shareholder categories.

The proposal to declare a dividend of ₹1.80 per equity share of ₹10 each (18% of face value) was also passed with near-unanimous support. Public institutions cast 5,10,418 votes in favor with zero dissent, while public non-institutional shareholders recorded 13,86,126 votes in favor against just 45 dissenting votes.

Director Reappointments Face Institutional Dissent

Two directors retiring by rotation were reappointed, though institutional investors registered significant dissent on both resolutions. Hashmukh I. Patel was reappointed with 95.47% overall support, while Munjal Mahendrabhai Patel secured 95.48% support.

What the Numbers Show

A clear divergence exists between promoter and institutional voting patterns regarding director reappointments. While promoters voted unanimously in favor of both directors, public institutions opposed approximately 99% of their polled votes on these specific resolutions. For Hashmukh I. Patel, institutions cast 5,06,936 votes against versus only 3,482 in favor. Similarly, for Munjal Mahendrabhai Patel, institutional dissent stood at 5,06,544 votes against compared to 3,874 in favor. This pattern suggests institutional investors may have governance concerns or proxy advisor recommendations influencing their voting behavior on board composition, despite the resolutions passing comfortably due to promoter majority support.

Other Approvals

The AGM also ratified the remuneration payable to cost auditors for FY27, which passed with 100.00% votes in favor among public institutions and negligible dissent from non-institutional shareholders. The scrutinizer’s report confirmed that all resolutions were passed with the requisite majority as ordinary resolutions.

Lincoln Pharmaceuticals appointed Pradeep Kumar Yadav as Senior General Manager, Quality Assurance, effective September 24, 2026. The appointment designates him as Senior Management Personnel under SEBI LODR regulations.

Yadav possesses over 20 years of experience in the pharmaceutical industry. His expertise includes Quality Management Systems, audit compliance, validation, and IPQA. He has managed international regulatory inspections by USFDA, MHRA, TGA, and WHO Geneva.

Appointment details

The company filed the intimation with the National Stock Exchange and BSE Limited on September 24, 2026. The appointment is effective immediately with no specified term limit. Yadav will be based at the manufacturing facility in Khatraj, Gujarat.

Regulatory compliance

The disclosure was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Trusha Kashish Shah, Company Secretary and Compliance Officer, signed the digital filing.

The appointment letter outlines a six-month probation period. It also specifies a two-year bond commitment, requiring a cheque equivalent to two months of CTC to secure training and infrastructure resources.